| 摘要 |
The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of a malignant cancer involving aberrant c-Met signaling. The present invention also provides methods for monitoring the status of a malignant cancer involving aberrant cMet signaling and monitoring how a patient with the malignant cancer is responding to anticancer drug therapy. |
